Marinus Pharmaceuticals, Inc. (MRNS)
$
0.55
Key metrics
Financial statements
Free cash flow per share
-2.0258
Market cap
30.4 Million
Price to sales ratio
0.9652
Debt to equity
-0.8390
Current ratio
1.6636
Income quality
0.8168
Average inventory
5.8 Million
ROE
4.9402
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Marinus Pharmaceuticals, Inc. is dedicated to the development and commercialization of treatments for patients dealing with rare genetic epilepsies and other seizure disorders. The financial data pertains to the fiscal year 2023. The company's product, ZTALMY, is an oral suspension designed for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, serving both adult and pediatric patient populations across acute and chronic care settings, as well as in-patient and self-administered environments. The company incurred an interest expense of $16,895,000.00 reflecting its debt servicing obligations. ZTALMY is designed to act on synaptic and extrasynaptic GABAA receptors, which is instrumental in its potential as an anti-seizure, antidepressant, and anxiolytic treatment. In addition, Marinus Pharmaceuticals is developing ganaxolone to address genetic epilepsy disorders including PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gastaut Syndrome. The total costs and expenses for the company are $162,474,000.00 reflecting its overall spending, while the operating income ratio is -4.24 indicating the company's operational profitability margin. Furthermore, Marinus has established a license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., along with a collaboration agreement with Orion Corporation, further enhancing its position in the market. The company's stock is identified with the symbol 'MRNS' in the market. The stock is affordable at $0.55 making it a feasible option for budget-conscious investors. With a high average trading volume of 1,810,773.00 the stock indicates strong liquidity, appealing to a diverse range of investors. Currently classified as a small-cap player, with a market capitalization of $30,370,175.00 Marinus Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The strategic positioning of the company alongside its financial health signals promising potential for stakeholders engaged in advancing medical treatments for rare conditions, solidifying its role as an integral part of the pharmaceutical ecosystem.
What is Marinus Pharmaceuticals, Inc. (MRNS)'s stock forecast?
Analysts predict Marinus Pharmaceuticals, Inc. stock to fluctuate between $0.22 (low) and $10.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Marinus Pharmaceuticals, Inc.'s market capitalization?
As of 2025-02-10, Marinus Pharmaceuticals, Inc.'s market cap is $30,370,175, based on 55,218,500 outstanding shares.
How does Marinus Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Marinus Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Marinus Pharmaceuticals, Inc. (MRNS) stock?
To buy Marinus Pharmaceuticals, Inc. (MRNS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MRNS. Place an order (Market, Limit, etc.).
What is the best time to invest in Marinus Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Marinus Pharmaceuticals, Inc. stock ever split?
Marinus Pharmaceuticals, Inc.'s last stock split was 1:4 on 2020-09-23.
How did Marinus Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $30,989,000 | EPS: -$2.63 | Growth: 415.69%.
Where can I find Marinus Pharmaceuticals, Inc.'s investor relations reports?
Visit https://marinuspharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Marinus Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Marinus Pharmaceuticals, Inc. stock?
All-time high: $82.88 (2015-08-05) | All-time low: $0.22 (2024-12-23).
What are the key trends affecting Marinus Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
businesswire.com
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmaceuticals, Inc. (NasdaqGM: MRNS) to Immedica Pharma AB. Under the terms of the proposed transaction, shareholders of Marinus will receive $0.55 in cash for each share of Marinus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
businesswire.com
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Marinus shareholders will receive $0.55 per share. Marinus insiders will receive substantial benefits as pa.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Marinus an.
businesswire.com
STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. The acquisition complements and further strengthens Immedica's gl.
zacks.com
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
businesswire.com
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June.
benzinga.com
Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.
businesswire.com
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis.
marketbeat.com
Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.
See all news
